Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ET140203 |
Synonyms | |
Therapy Description |
ET140203 are autologous T lymphocytes that have been engineered to express a T-cell receptor mimetic (TCRm) construct that targets an undisclosed tumor-associated antigen, potentially leading to cytotoxic T-cell mediated tumor cell killing (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ET140203 | ET 140203|ET-140203 | ET140203 are autologous T lymphocytes that have been engineered to express a T-cell receptor mimetic (TCRm) construct that targets an undisclosed tumor-associated antigen, potentially leading to cytotoxic T-cell mediated tumor cell killing (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04634357 | Phase Ib/II | ET140203 | ET140203 T-Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma (ARYA-2) | Recruiting | USA | 0 |
NCT04502082 | Phase Ib/II | ET140203 | Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ET121) | Terminated | USA | 0 |